Published

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Journal of psychosocial nursing and mental health services
Date: 2016-07-01
Source: PubMed
DOI: 10.3928/02793695-20160616-09
PubMed: 27362381

Authors

Howland RH

Watch author

Derived topics and classifications

psilocybin Depression Anxiety PTSD Addiction Receptor Pharmacology Clinical Trial Drug Interactions Clinical Trial

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor.2016-07-01

Related papers

Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness (PDR-Study)ClinicalTrials.gov · 2025-05-28 S1 Appendix - Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trialFigshare · 2025-09-19 Comparative Acute Effects of LSD, Psilocybin and Mescaline in a Random-Order Placebo-Controlled Cross-Over Study in Healthy SubjectsClinicalTrials.gov · 2024-01-24 Effects of Serotonin Transporter Inhibition on the Subjective Response to Psilocybin in Healthy SubjectsClinicalTrials.gov · 2020-12-01 Role of the Serotonin 5-HT2A Receptor in Mescaline-induced Altered States of ConsciousnessClinicalTrials.gov · 2023-03-29 Psilocybin for alcohol use disorder: Rationale and design considerations for a randomized controlled trial.Contemporary clinical trials · 2022-12-01 Effect of MDMA-assisted therapy on mood and anxiety symptoms in advanced-stage cancer (EMMAC): study protocol for a double-blind, randomised controlled trial.Trials · 2024-05-21 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10